Budesonide is a medication used in this trial to help control asthma symptoms. It works by reducing inflammation in the airways, making it easier to breathe.

Glycopyrronium is included in the trial as part of a combination therapy. It helps to relax and open the airways in the lungs, which can improve breathing in people with asthma.

Formoterol Fumarate is another medication used in the trial. It is a long-acting bronchodilator that helps to keep the airways open, making it easier for asthma patients to breathe.

Symbicort is a combination inhaler that contains both Budesonide and Formoterol Fumarate. It is used in the trial to compare its effectiveness with other treatments in improving lung function and reducing asthma exacerbations.

Severe and inadequately controlled asthma – This is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty in breathing. Individuals with this form of asthma experience frequent and severe symptoms such as wheezing, coughing, shortness of breath, and chest tightness. The condition is considered inadequately controlled when these symptoms persist despite the use of standard asthma medications. Over time, the inflammation can cause the airways to become more sensitive and reactive to various triggers, such as allergens, exercise, or cold air. This can result in asthma exacerbations, which are episodes of worsening symptoms that may require additional medical attention. The progression of the disease can vary, with some individuals experiencing more frequent or severe exacerbations than others.